Form 4: Geron Corp Director Dawn Carter Bir Reports Stock Option Grant

Director Dawn Carter Bir reports the acquisition of stock options in Geron Corp.

Summary

• Dawn Carter Bir, a director of Geron Corporation, filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Bir on May 09, 2024.
• Bir acquired options to purchase 180,000 shares of Geron's common stock at an exercise price of $3.88 per share.
• The options vest on the earlier of the next annual meeting of the Company's stockholders or the first anniversary of the grant date, subject to continuous service.
• Following the transaction, Bir directly owns derivative securities for 180,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The size of the grant is typical for a director role, but the specific value depends on Geron's stock performance.
• Companies like Amgen, Gilead, and Biogen also use stock options extensively in their executive compensation plans.

Stakeholder Impact

• The stock option grant could incentivize the director to make decisions that increase shareholder value.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates